List of SBIR/STTR awards granted to NovoBiotic Pharmaceuticals
NovoBiotic PharmaceuticalsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in April, 2020 for $299,505.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI152675-01 | Phase I | 299,505 | April 22, 2020 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals in February, 2018 for $1,995,921.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AI118000-03 | Phase II | 1,995,921 | February 14, 2018 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals in April, 2019 for $999,992.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AI136137-02A1 | Phase II | 999,992 | April 15, 2019 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals in September, 2022 for $999,995.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI172478-01 | Phase II | 999,995 | September 1, 2022 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in January, 2018 for $231,409.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI136137-01 | Phase I | 231,409 | January 10, 2018 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals in June, 2020 for $999,978.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI152657-01A1 | Phase II | 999,978 | June 15, 2020 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in May, 2014 for $597,402.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI108042-01A1 | Phase I | 597,402 | May 1, 2014 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in February, 2015 for $219,069.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI118058-01 | Phase I | 219,069 | February 1, 2015 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals in December, 2012 for $2,967,717.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI091224-03 | Phase II | 2,967,717 | December 15, 2012 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in August, 2017 for $586,229.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI134274-01 | Phase I | 586,229 | August 9, 2017 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals in February, 2015 for $1,490,624.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44AI118000-01 | Phase II | 1,490,624 | February 1, 2015 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in July, 2015 for $224,356.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI120338-01 | Phase I | 224,356 | July 1, 2015 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in June, 2016 for $1,484,593.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44AI122425-01A1 | Phase I | 1,484,593 | June 16, 2016 | |||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in January, 2013 for $147,276.0 USD from the National Science Foundation. | SBIR | 1248398 | Phase I | 147,276 | January 1, 2013 | |||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals for $5,412,780.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI063616-03 | Phase II | 5,412,780 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $299,258.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI072895-01 | Phase I | 299,258 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $471,409.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI063616-01 | Phase I | 471,409 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $598,976.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI091224-01 | Phase I | 598,976 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $599,946.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI096791-01A1 | Phase I | 599,946 | ||||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals for $2,998,500.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI072895-03A1 | Phase II | 2,998,500 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $597,943.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI085612-01 | Phase I | 597,943 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $598,617.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI078572-01 | Phase I | 598,617 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals for $999,578.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI063768-01A1 | Phase I | 999,578 | ||||||||
A SBIR Phase II contract was awarded to NovoBiotic Pharmaceuticals for $2,998,360.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI078572-03 | Phase II | 2,998,360 | ||||||||
A SBIR Phase I contract was awarded to NovoBiotic Pharmaceuticals in May, 2023 for $299,997.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI174320-01A1 | Phase I | 299,997 | May 9, 2023 |
